logo

Xtl Biopharmaceutica (XTLB)



Trade XTLB now with
  Date
  Headline
7/24/2018 9:12:05 AM XTL Biopharma HY Net Income $909K Or $0.002/shr Vs. Loss Of $2.40 Mln Or $0.006/shr Prior Year
9/26/2017 9:25:32 AM XTL Biopharmaceuticals H1 Operating Loss $2,365 Thousand Or $0.006 Per Share
9/12/2017 10:26:31 AM XTL Unveils Additional Expanded HCDR1 Preclinical Data For Treatment Of Sjogren's Syndrome
3/30/2017 9:06:39 AM XTL Biopharmaceuticals FY Net Loss $2.5 Mln Or $0.009/shr Vs. Loss $4.3 Mln Or $0.017/shr Prior Year
3/1/2017 8:33:34 AM XTL Biopharma Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement
2/17/2017 8:02:20 AM XTL Biopharmaceuticals Announces $2.5 Mln Registered Direct Offering
2/13/2017 9:12:49 AM XTL Biopharma Expands Clinical Advisory Board To Support Phase II Study Of HCDR1 In Sjogren's Syndrome
1/5/2017 8:43:39 AM XTL Intends To Pursue Sjögren's Syndrome As Second Indication For Its Lead Drug Candidate HCDR1
9/27/2016 8:36:08 AM XTL Biopharma Q2 Loss/shr $0.002 Vs. Loss/shr $0.001 Prior Year
6/1/2016 8:37:44 AM XTL Biopharma Q1 Net Loss $600K Or $0.002/shr Vs. Loss $1.1 Mln Or $0.005/shr Last Year
3/31/2016 9:49:13 AM XTL Biopharmaceuticals FY Total Net Loss $4.3 Mln Or $0.017/shrvs. Loss $2.9 Mln Or $0.011/shr Last Year
3/21/2016 8:33:20 AM XTL Biopharma Completes Phase 2 Trial Design For Lead Compound HCDR1 In The Treatment Of Lupus
2/22/2016 9:04:56 AM XTL Biopharma Gets European Medicines Agency's SME Status
2/10/2016 8:36:04 AM XTL' Lupus Drug HCDR1 Granted Patent For Pharmaceutical Composition & Manufacturing Processes